ADVERTISEMENT
News
MariGen - Kerecis
05/28/2024
Kerecis presented data from the ODIN RCT, an EU multicenter trial for UT Grade 2 and 3 DFUs. The 255-patient trial compared FSG to SOC with the primary endpoint percent closure at 16 weeks. Healing in the FSG group was 44% at 16 weeks and 26% in the SOC (P<0.001). SmartTRAK at SAWC Spring 2024
